Association of class I HLA antigens with the clinical manifestations of Turkish patients with Behçet's disease

2002 ◽  
Vol 27 (6) ◽  
pp. 498-501 ◽  
Author(s):  
T. I. Kaya ◽  
U. Tursen ◽  
A. Gurler ◽  
H. Dur
2014 ◽  
Vol 13 (3) ◽  
pp. 4788-4796 ◽  
Author(s):  
D.D. Demirseren ◽  
G.G. Ceylan ◽  
G. Akoglu ◽  
S. Emre ◽  
S. Erten ◽  
...  

2011 ◽  
Vol 38 (4) ◽  
pp. 295-301 ◽  
Author(s):  
A. A. Özçimen ◽  
K. Dilek ◽  
Ü. Bingöl ◽  
H. Sarıcaoğlu ◽  
A. Sarandöl ◽  
...  

2009 ◽  
Vol 30 (2) ◽  
pp. 285-289 ◽  
Author(s):  
Mortaza Bonyadi ◽  
Zohreh Jahanafrooz ◽  
Mohsen Esmaeili ◽  
Susan Kolahi ◽  
Alireza Khabazi ◽  
...  

Author(s):  
Anthony Nguyen ◽  
Shubhra Upadhyay ◽  
Muhammad Ali Javaid ◽  
Abdul Moiz Qureshi ◽  
Shahan Haseeb ◽  
...  

Background: Behcet’s Disease (BD) is a complex inflammatory vascular disorder that follows a relapsing-remitting course with diverse clinical manifestations. The prevalence of the disease varies throughout the globe and targets different age groups. There are many variations of BD, however, intestinal BD is not only more common but has many signs and symptoms. Summary: BD is a relapsing-remitting inflammatory vascular disorder with multiple system involvement, affecting vessels of all types and sizes that targets young adults. The etiology of BD is unknown but many factors including genetic mechanisms, vascular changes, hypercoagulability and dysregulation of immune function are believed to be responsible. BD usually presents with signs and symptoms of ulcerative disease of the small intestine; endoscopy being consistent with the clinical manifestations. The mainstay of treatment depends upon the severity of the disease. Corticosteroids are recommended for severe forms of the disease and aminosalicylic acids are used in maintaining remission in mild to moderate forms of the disease. Key messages: In this review, we have tried to summarize in the present review the clinical manifestations, differential diagnoses and management of intestinal BD. Hopefully, this review will enable health policymakers to ponder over establishing clear endpoints for treatment, surveillance investigations and creating robust algorithms.


2018 ◽  
Vol 48 (2) ◽  
pp. 121-129 ◽  
Author(s):  
Mohanad M. Elfishawi ◽  
Fatema Elgengehy ◽  
Ghada Mossallam ◽  
Sally Elfishawi ◽  
Mostafa Alfishawy ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document